Limits...
Targeting of tumor endothelial cells combining 2 Gy/day of X-ray with Everolimus is the effective modality for overcoming clinically relevant radioresistant tumors.

Kuwahara Y, Mori M, Kitahara S, Fukumoto M, Ezaki T, Mori S, Echigo S, Ohkubo Y, Fukumoto M - Cancer Med (2014)

Bottom Line: Radiotherapy is widely used to treat cancer because it has the advantage of physically and functionally conserving the affected organ.Everolimus with FR markedly reduced SAS and SAS-R tumor volumes.We conclude that FR combined with Everolimus may be an effective modality to overcome radioresistant tumors via targeting tumor ECs.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, 980-8575, Japan.

Show MeSH

Related in: MedlinePlus

(A) Immunohistochemical analysis of CD34-positive blood vessels (arrow heads) in xenografted tumors without any treatments. CD34 immunostaining confirmed that MVD in SAS-R tumors was higher than in SAS tumors. (B) Blood vessel density determined by tomato lectin labeling in SAS and SAS-R tumors. Tomato lectin labeling of the luminal endothelial cell surface showed that MVD with blood flow was higher in SAS-R tumors compared to in SAS tumors. (C) Immunohistochemical staining of VEGF-A. SAS-R tumor cells had stronger immunostaining for VEGF-A than SAS tumor cells. (D) VEGF-A production from SAS and SAS-R cells in vitro determined by ELISA. Twofold secretion of VEGF-A from SAS-R cells compared to SAS was detected. *P < 0.01. MVD, microvessel density; VEGF, vascular endothelial growth factor.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3987081&req=5

fig02: (A) Immunohistochemical analysis of CD34-positive blood vessels (arrow heads) in xenografted tumors without any treatments. CD34 immunostaining confirmed that MVD in SAS-R tumors was higher than in SAS tumors. (B) Blood vessel density determined by tomato lectin labeling in SAS and SAS-R tumors. Tomato lectin labeling of the luminal endothelial cell surface showed that MVD with blood flow was higher in SAS-R tumors compared to in SAS tumors. (C) Immunohistochemical staining of VEGF-A. SAS-R tumor cells had stronger immunostaining for VEGF-A than SAS tumor cells. (D) VEGF-A production from SAS and SAS-R cells in vitro determined by ELISA. Twofold secretion of VEGF-A from SAS-R cells compared to SAS was detected. *P < 0.01. MVD, microvessel density; VEGF, vascular endothelial growth factor.

Mentions: Connective tissues were more abundant in SAS-R tumors than in SAS tumors (Fig. 1B). This observation prompted us to examine MVD in SAS and SAS-R tumors. CD34 immunostaining confirmed that MVD in SAS-R tumors was higher than in SAS tumors (Fig. 2A). Tomato lectin labeling of the luminal EC surface showed that MVD with blood flow was higher in SAS-R tumors compared to in SAS tumors (Fig. 2B). This suggested that angiogenesis was activated in SAS-R tumors. MVD was also higher in HeLa-R tumors than in HeLa tumors (data not shown).


Targeting of tumor endothelial cells combining 2 Gy/day of X-ray with Everolimus is the effective modality for overcoming clinically relevant radioresistant tumors.

Kuwahara Y, Mori M, Kitahara S, Fukumoto M, Ezaki T, Mori S, Echigo S, Ohkubo Y, Fukumoto M - Cancer Med (2014)

(A) Immunohistochemical analysis of CD34-positive blood vessels (arrow heads) in xenografted tumors without any treatments. CD34 immunostaining confirmed that MVD in SAS-R tumors was higher than in SAS tumors. (B) Blood vessel density determined by tomato lectin labeling in SAS and SAS-R tumors. Tomato lectin labeling of the luminal endothelial cell surface showed that MVD with blood flow was higher in SAS-R tumors compared to in SAS tumors. (C) Immunohistochemical staining of VEGF-A. SAS-R tumor cells had stronger immunostaining for VEGF-A than SAS tumor cells. (D) VEGF-A production from SAS and SAS-R cells in vitro determined by ELISA. Twofold secretion of VEGF-A from SAS-R cells compared to SAS was detected. *P < 0.01. MVD, microvessel density; VEGF, vascular endothelial growth factor.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3987081&req=5

fig02: (A) Immunohistochemical analysis of CD34-positive blood vessels (arrow heads) in xenografted tumors without any treatments. CD34 immunostaining confirmed that MVD in SAS-R tumors was higher than in SAS tumors. (B) Blood vessel density determined by tomato lectin labeling in SAS and SAS-R tumors. Tomato lectin labeling of the luminal endothelial cell surface showed that MVD with blood flow was higher in SAS-R tumors compared to in SAS tumors. (C) Immunohistochemical staining of VEGF-A. SAS-R tumor cells had stronger immunostaining for VEGF-A than SAS tumor cells. (D) VEGF-A production from SAS and SAS-R cells in vitro determined by ELISA. Twofold secretion of VEGF-A from SAS-R cells compared to SAS was detected. *P < 0.01. MVD, microvessel density; VEGF, vascular endothelial growth factor.
Mentions: Connective tissues were more abundant in SAS-R tumors than in SAS tumors (Fig. 1B). This observation prompted us to examine MVD in SAS and SAS-R tumors. CD34 immunostaining confirmed that MVD in SAS-R tumors was higher than in SAS tumors (Fig. 2A). Tomato lectin labeling of the luminal EC surface showed that MVD with blood flow was higher in SAS-R tumors compared to in SAS tumors (Fig. 2B). This suggested that angiogenesis was activated in SAS-R tumors. MVD was also higher in HeLa-R tumors than in HeLa tumors (data not shown).

Bottom Line: Radiotherapy is widely used to treat cancer because it has the advantage of physically and functionally conserving the affected organ.Everolimus with FR markedly reduced SAS and SAS-R tumor volumes.We conclude that FR combined with Everolimus may be an effective modality to overcome radioresistant tumors via targeting tumor ECs.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, 980-8575, Japan.

Show MeSH
Related in: MedlinePlus